Macular Degeneration
5 videos · updated daily
56:34 Luxa's RPE Stem Cell Therapy: Phase 1 Trial in AMD
Dr. Jeffrey Stern, co-founder of the Neural Stem Cell Institute and co-CEO of Luxa Biotechnology, discusses its stem cell-derived RPE therapy, early results from a first-in-human Phase 1 trial in late-stage AMD and plans to include inherited retinal disease.
9:34 Long Term Followup of Intravitreal Gene Therapy for Neovascular AMD
Retina Synthesis discusses three-year results from the Phase 2 trial of Adverum's intravitreal gene therapy with Dr. Dilsher Dhoot of California Retina Consultants.
27:43 EyeStem's RPE Cell Replacement Therapy
Dr. Jogin Desai, Founder and CEO of EyeStem, describes for the Choroideremia Research Foundation Phase 1 results of its RPE cell replacement therapy in dry AMD and geographic atrophy, which by June 2026 had moved into a Phase 2 study.
12:56 OCT-based Endpoints in Clinical Trials in Intermediate AMD – Robyn Guymer
Robyn Guymer on OCT-based endpoints in trials of intermediate age-related macular degeneration, at the International SPECTRALIS Symposium.
7:02 Wet AMD Treatment from Opthea
Joel Naor, MD, MSC, MBA from Opthea discusses Wet AMD and potential treatment options.